ArticleBMC cancer2026
Outcome analysis and associations with Charlson comorbidity index in the early-stage lung cancer patients treated with stereotactic radiotherapy.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLung stereotactic body radiotherapy (SBRT) is the standard of care for patients with inoperable early-stage non-small cell lung cancer (NSCLC), who frequently have significant comorbidities. There is no standardised method to predict how age and comorbidities influence SBRT efficacy or toxicity. The Charlson Comorbidity Index (CCI) and its age-adjusted variant (aCCI) have been proposed as prognostic tools, though their predictive value remains uncertain. This study assessed the prognostic relevance of the CCI and aCCI in patients undergoing SBRT for early-stage NSCLC.
methodsThis retrospective single-institution study included patients with NSCLC treated with SBRT between January 2010 and December 2023. Patients receiving standard SBRT dose-fractionation for peripheral, central, and ultracentral tumours were eligible. CCI and aCCI scores were calculated for all patients. The primary objective was to compare overall survival (OS) between patients with low (< 2) and high (≥ 2) CCI scores. Secondary outcomes included associations of CCI and aCCI with OS, cancer-specific survival (CSS), local failure (LF), regional failure (RF), distant failure (DF), and treatment-related toxicity. Cox proportional hazards regression was used.
resultsA total of 170 patients were included, with a median age of 77 years (range: 51–93). After a median follow-up of 36.4 months, 68 deaths occurred, including 24 cancer-specific deaths. Median OS was 59.4 months (95% CI: 49.9–104.1), while median CSS was not reached. High CCI (> 2) was not associated with worse OS (univariate: HR 0.97, 95% CI: 0.43–2.16, p = 0.93; multivariate: HR 0.16, 95% CI: 0.03–0.92, p = 0.04). High aCCI (> 6) was also not significantly associated with OS (HR 1.02, 95% CI: 0.43–2.38, p = 0.97). Patients with peripheral tumours had a significantly higher risk of death than those with central tumours (HR 4.7 × 10⁹, 95% CI: 1.1 × 10⁹–2.01 × 10¹⁰, p < 0.001). No other variables significantly influenced survival. SBRT was well tolerated, with no grade 4–5 toxicities or treatment-related deaths.
conclusionsThe CCI and aCCI did not predict overall or disease-specific survival in patients treated with SBRT for early-stage NSCLC. These findings suggest that current comorbidity indices may be inadequate in this population and highlight the need for improved prognostic tools to guide treatment decisions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.